Codex DNA Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional...
23 June 2021 - 6:10AM
Codex DNA, Inc. (Nasdaq: DNAY) today announced the closing of its
initial public offering of 7,666,664 shares of common stock,
including the full exercise of the underwriters’ option to purchase
up to 999,999 additional shares of common stock, at a public
offering price of $16.00 per share. The aggregate gross proceeds to
Codex DNA from the offering were approximately $122.7 million,
before deducting underwriting discounts and commissions and other
offering expenses. All of the shares in the offering were offered
by Codex DNA.
Codex DNA’s common stock began trading on The Nasdaq Global
Select Market on June 18, 2021 under the ticker symbol "DNAY."
Jefferies LLC, Cowen and Company, LLC and KeyBanc Capital
Markets Inc. are acting as joint book-running managers for the
proposed offering.
A registration statement relating to these securities has been
filed with the Securities and Exchange Commission and
became effective on June 17, 2021. The offering was made only
by means of a prospectus. Copies of the final prospectus relating
to this offering may be obtained from Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd
Floor, New York, NY 10022, or by e-mail at
Prospectus_Department@Jefferies.com; or by telephone at (877)
821-7388; Cowen and Company, LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attention:
Prospectus Department, or by e-mail at
PostSaleManualRequests@broadridge.com; or by telephone at (833)
297-2926; KeyBanc Capital Markets Inc., Attention: Equity
Syndicate, 127 Public Square, 4th Floor, Cleveland, Ohio 44114, or
by telephone at (800) 859-1783.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Codex DNA
Codex DNA is a synthetic biology company focused on enabling
researchers to rapidly, accurately and reproducibly build or
“write” high-quality synthetic DNA and mRNA that is ready to use in
many downstream synthetic biology enabled markets. Codex DNA’s
synthetic biology solution addresses the bottlenecks across the
multi-step process of building DNA and mRNA, as well as the
significant limitations of existing solutions that prevent the
rapid building of virtually error-free DNA and mRNA at a useable
scale. A key part of Codex DNA’s solution is the BioXp™ system, an
end-to-end automated workstation that fits on the benchtop and is
broadly accessible due to its ease-of-use and hands-free
automation. Codex DNA believes the BioXp™ system can democratize
synthetic biology by simplifying the process of building DNA and
mRNA, thereby accelerating the discovery, development and
production of novel high-value products, including antibody-based
biologics, mRNA-based vaccines and therapeutics and precision
medicines.
Contact Information:
Jennifer McNealey
Jennifer@codexdna.com
Codex DNA (NASDAQ:DNAY)
Historical Stock Chart
From Apr 2024 to May 2024
Codex DNA (NASDAQ:DNAY)
Historical Stock Chart
From May 2023 to May 2024